InnoPharmax Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Taipei Taiwan (2005)

Organization Overview

First Clinical Trial
2012
NCT01678690
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

InnoPharmax Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Biliary Tract Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 8